Page 3«..2345..1020..»

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Posted: November 12, 2024 at 2:47 am

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.

The rest is here:
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Posted in Global News Feed | Comments Off on Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Celldex Therapeutics to Present at Upcoming Investor Conferences

Posted: November 12, 2024 at 2:47 am

HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:

Read the original here:
Celldex Therapeutics to Present at Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on Celldex Therapeutics to Present at Upcoming Investor Conferences

Assertio Reports Third Quarter 2024 Financial Results

Posted: November 12, 2024 at 2:47 am

Third Quarter Total Net Product Sales of $28.7 Million

Read the original:
Assertio Reports Third Quarter 2024 Financial Results

Posted in Global News Feed | Comments Off on Assertio Reports Third Quarter 2024 Financial Results

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update

Posted: November 12, 2024 at 2:47 am

-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) ---- 50% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.50 [90% CI, 0.20-1.28]) --

Read more:
Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update

Posted in Global News Feed | Comments Off on Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update

Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering

Posted: November 12, 2024 at 2:47 am

Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC”

Read the original here:
Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering

Posted in Global News Feed | Comments Off on Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Posted: November 12, 2024 at 2:47 am

FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time.

Read more from the original source:
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Posted in Global News Feed | Comments Off on Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

IO Biotech Announces Participation in Upcoming Investor Conferences

Posted: November 12, 2024 at 2:47 am

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences:

Excerpt from:
IO Biotech Announces Participation in Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on IO Biotech Announces Participation in Upcoming Investor Conferences

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Posted: November 12, 2024 at 2:47 am

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 –

See the original post here:
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker

Posted: November 12, 2024 at 2:47 am

Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety

Original post:
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker

Posted in Global News Feed | Comments Off on HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker

Regeneron Announces Investor Conference Presentations

Posted: November 12, 2024 at 2:47 am

TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

See more here:
Regeneron Announces Investor Conference Presentations

Posted in Global News Feed | Comments Off on Regeneron Announces Investor Conference Presentations

Page 3«..2345..1020..»